Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "Elutia Inc.", but the filing text identifies the registrant as Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2021
Reporting Period: Quarter ended March 31, 2021
Business Context: The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Silver Spring, MD. Its Class A Common Stock trades on The Nasdaq Global Market under the symbol "AZYO".
Key Financial Metrics
The provided Form 8-K text serves as a notification of results and does not contain specific financial data points. It references a press release (Exhibit 99.1) for the full details. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. It only states that financial results for the quarter ended March 31, 2021, were announced via a press release.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management issued a press release on May 4, 2021, announcing financial results. The full text of this commentary is contained in Exhibit 99.1, which is not included in the provided input.
Guidance and Outlook: No specific forward-looking guidance or outlook is detailed in the Form 8-K text itself.
Risks and Contingencies: No specific risks or contingencies are enumerated in the provided text, other than the standard disclaimer that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 4, 2021), as they are not present in the 8-K body.
- Confirm the company name discrepancy: The filing is for Aziyo Biologics, Inc., not Elutia Inc.
- Check the Nasdaq Global Market trading status for ticker AZYO to ensure current liquidity and trading volume.
- Review the full press release for any updates on clinical trial progress or regulatory milestones, which are typical for biotechnology firms but not detailed in this summary.